BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8401249)

  • 1. Interleukin 2 treatment in acute myelogenous leukemia.
    Mandelli F; Vignetti M; Tosti S; Andrizzi C; Foa R; Meloni G
    Stem Cells; 1993 Jul; 11(4):263-8. PubMed ID: 8401249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
    Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
    Margolin K; Forman SJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
    Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
    Meloni G; Vignetti M; Avvisati G; Capria S; Micozzi A; Giona F; Mandelli F
    Bone Marrow Transplant; 1996 Oct; 18(4):693-8. PubMed ID: 8899182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation for adult acute leukemia.
    Ball ED; Rybka WB
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):201-31. PubMed ID: 8449859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
    de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
    Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2.
    Speletas M; Ritis K; Bourikas G
    Haematologica; 1996; 81(4):346-8. PubMed ID: 8870381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplantation in children with acute myeloblastic leukemia: report from the Italian National Pediatric Registry (AIEOP-BMT).
    Vignetti M; Rondelli R; Locatelli F; Lanino E; Miniero R; Rossetti F; Meloni G
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():59-62. PubMed ID: 8932801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
    Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S; Lin HS; Dipersio J; Adkins D
    Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
    Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
    Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
    Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of early treatment response in children with acute myeloid leukemia].
    Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.